SanBio Co., Ltd. and its subsidiary SanBio, Inc. make up the group. The group announced procurement of funds totaling ¥11,000 million in the current fiscal year. The funds were procured upon completion of the exercise of share acquisition rights that carry an exercise price adjustment clause issued on April 6, 2018. SanBio said the procured funds will be used as investments for medium-term growth. The announcement was issued by the company's management administration and includes a contact, Masahito Kumagae. The filing does not provide additional financing breakdowns or investor names. SanBio develops cell‑based regenerative medicine therapies targeting neurological disorders, with its proprietary product SB623 central to clinical programs. SB623 is in a Phase 2b clinical trial (ACTIsSIMA) for chronic motor impairments from stroke and in a global Phase 2 trial for motor impairment after traumatic brain injury. The company reports cell‑based products at various stages of research, development and clinical testing. SanBio operates out of Tokyo and Mountain View and is led by CEO Keita Mori and CMO/Head of Research Dr. Damien Bates. The firm is partnering with Sumitomo Dainippon Pharma for SB623 development in the United States and Canada and has joint sponsorship arrangements with Sunovion for the ACTIsSIMA trial. The recent external funding described in the article is a grant supporting its Phase 2b program.

Total raised

$120M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2018